Establishment Labs Holdings (ESTA) Panoramica del titolo
Establishment Labs Holdings Inc. è una società di tecnologia medica che produce e commercializza dispositivi medici per la chirurgia estetica e ricostruttiva del seno in Europa, Medio Oriente, Africa, America Latina, Asia e Stati Uniti. Maggiori dettagli
| Punteggio fiocco di neve | |
|---|---|
| Valutazione | 1/6 |
| Crescita futura | 6/6 |
| Prestazioni passate | 0/6 |
| Salute finanziaria | 2/6 |
| Dividendi | 0/6 |
Premi
Analisi del rischio
Non sono stati rilevati rischi per ESTA dai nostri controlli di rischio.
ESTA Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
Analyst Price Targets
Concorrenti di Establishment Labs Holdings Inc.
Storia dei prezzi e prestazioni
| Prezzi storici delle azioni | |
|---|---|
| Prezzo attuale dell'azione | US$72.67 |
| Massimo di 52 settimane | US$97.59 |
| Minimo di 52 settimane | US$36.53 |
| Beta | 1.09 |
| Variazione di 1 mese | -22.58% |
| Variazione a 3 mesi | 0.66% |
| Variazione di 1 anno | 66.54% |
| Variazione a 3 anni | 32.08% |
| Variazione a 5 anni | 0.28% |
| Variazione dall'IPO | 193.62% |
Notizie e aggiornamenti recenti
Aggiornamento narrativa • Aug 20
ESTA: Q2 Execution And New Reconstruction Cycle Will Support 2026 Outlook
The updated Analyst Price Target for Establishment Labs Holdings changes from $95.33 to $102.44. Analysts point to recent price target increases from firms such as Citi, TD Cowen, Mizuho and BTIG, which they say reflect confidence in the Q2 report, the valuation after the recent pullback, and the upcoming reconstruction product cycle and U.S. launches.Articolo di analisi • Aug 10
Establishment Labs Holdings Inc. (NASDAQ:ESTA) Released Earnings Last Week And Analysts Lifted Their Price Target To US$102
It's been a mediocre week for Establishment Labs Holdings Inc. ( NASDAQ:ESTA ) shareholders, with the stock dropping...Recent updates
Aggiornamento narrativa • Aug 20
ESTA: Q2 Execution And New Reconstruction Cycle Will Support 2026 Outlook
The updated Analyst Price Target for Establishment Labs Holdings changes from $95.33 to $102.44. Analysts point to recent price target increases from firms such as Citi, TD Cowen, Mizuho and BTIG, which they say reflect confidence in the Q2 report, the valuation after the recent pullback, and the upcoming reconstruction product cycle and U.S. launches.Articolo di analisi • Aug 10
Establishment Labs Holdings Inc. (NASDAQ:ESTA) Released Earnings Last Week And Analysts Lifted Their Price Target To US$102
It's been a mediocre week for Establishment Labs Holdings Inc. ( NASDAQ:ESTA ) shareholders, with the stock dropping...
Aggiornamento narrativa • Aug 06
ESTA: Upcoming Earnings And Margin Outlook Will Support Repricing
Analysts have lifted their fair value estimate for Establishment Labs Holdings to $117 from $100, citing a lower assumed discount rate, a higher profit margin profile, and recent price target increases across the Street as support for the new target range. Analyst Commentary Recent Street research on Establishment Labs Holdings points to a more constructive tone heading into upcoming earnings updates.Aggiornamento narrativa • Jul 23
ESTA: Q2 Earnings Preview And 2026 Outlook Will Temper Sector Volatility
The analyst price target for Establishment Labs Holdings has been raised by $4.67 to reflect updated views on fair value and assumptions around revenue, profit margins and future P/E, as several firms recently lifted their targets into a Q2 earnings preview. Analyst Commentary Recent research on Establishment Labs Holdings points to a more constructive tone around the stock into Q2 earnings, with several firms lifting their price targets while still flagging sector level risks in medical devices.
Aggiornamento narrativa • Jul 08
ESTA: Index Additions And 2026 Guidance Will Support Measured Repricing
Analysts have modestly lifted their fair value estimate for Establishment Labs Holdings to $84, supported by a higher Street price target of $92 and updated assumptions around revenue growth, profit margins, and future P/E. Analyst Commentary Recent Street research on Establishment Labs Holdings points to a more measured stance, even as the official price targets cited are above the current fair value estimate.Aggiornamento narrativa • Jun 18
ESTA: Fair 2026 Outlook Will Balance Overdone Selloff And Execution Risks
Analysts have nudged their price target on Establishment Labs Holdings higher to about $90.67 from $89, citing what they view as an overdone selloff and updated views on fair value and future earnings multiples. Analyst Commentary Recent Street research on Establishment Labs Holdings highlights a mix of optimism and caution as analysts reassess what they view as an overdone selloff and revisit their valuation work.Aggiornamento narrativa • Jun 03
ESTA: Rebased Expectations And Raised 2026 Guidance Will Support Measured Repricing
Analysts have lifted their price target on Establishment Labs Holdings by $11 to $74, pointing to what they see as an overdone selloff and reaffirming that sector fundamentals in medical technology remain healthy despite recent volatility. Analyst Commentary Recent research updates on Establishment Labs Holdings highlight a mixed backdrop, with some analysts pointing to what they view as an overdone selloff while others trim expectations and flag risks around execution and valuation.Aggiornamento narrativa • May 17
ESTA: Raised 2026 Guidance And Profitability Will Support Bullish Repricing
Analysts have lifted their consolidated price target on Establishment Labs to $76.00, supported by recent research that cites updated Q4-driven models, sustained profitability, and reinforced confidence in upcoming US guidance. Analyst Commentary Street research around Establishment Labs Holdings has been active, with multiple firms updating their models following the latest Q4 results and guidance.Aggiornamento narrativa • Apr 29
ESTA: Mixed Research Views And 2026 Outlook Will Shape Earnings Profile
Narrative Update on Establishment Labs Holdings The updated analyst price target for Establishment Labs Holdings has shifted from about $75 to roughly $69, as analysts factor in slightly softer modeled revenue growth and profit margins, partly offset by a higher assumed future P/E and mixed recent price target moves across the Street. Analyst Commentary Recent Street research on Establishment Labs Holdings presents a mixed picture, with some more optimistic voices balancing out a set of cautious adjustments.Aggiornamento narrativa • Apr 14
ESTA: Sustained Adj EBITDA Profitability And US Guidance Will Support Repricing
Analysts have revised the price target for Establishment Labs Holdings to $100, reflecting updated views on discount rates, margins, and long term P/E assumptions following recent sector wide model adjustments and company specific Q4 and guidance commentary. Analyst Commentary Recent research coverage on Establishment Labs Holdings has centered on how the company’s Q4 results, guidance, and sector wide model resets feed into valuation frameworks, particularly around updated P/E assumptions and revised discount rates.Aggiornamento narrativa • Mar 31
ESTA: Sustained EBITDA Profitability And 2026 Guidance Will Support Stronger Outlook
Narrative Update on Establishment Labs Holdings The updated analyst price target of $89.00 for Establishment Labs Holdings, which held steady compared with the prior $89 level, reflects analysts balancing recent target increases tied to Q4 results and 2026 guidance with a sector wide recalibration in medical technology and a view among some that the recent selloff was unwarranted and overdone. Analyst Commentary Recent Street research on Establishment Labs Holdings highlights a mix of supportive and cautious views as analysts update their models following Q4 results, 2026 guidance and volatility across the medical technology group.Aggiornamento narrativa • Mar 17
ESTA: Sustained EBITDA Profitability And U S Guidance Will Support Stronger Outlook
Analysts have nudged the fair value estimate for Establishment Labs Holdings to $89.00, reflecting updated price targets across the Street that incorporate recent Q4 results, refreshed guidance, and sector wide medtech adjustments. Analyst Commentary Street research around Establishment Labs Holdings has shifted meaningfully following Q4 results and updated guidance, with a spread of targets from $74 to $100 helping anchor the new $89.00 fair value estimate.Aggiornamento narrativa • Mar 03
ESTA: Sustained Adj EBITDA Profitability And US Guidance Will Drive Repricing
Analysts have raised their average fair value estimate for Establishment Labs Holdings to $100 from $90, citing recent price target increases and updated models that reflect Q4 results, sustained Adj. EBITDA profitability, and a more constructive view on 2026 and US guidance.Aggiornamento narrativa • Feb 17
ESTA: 2025 Revenue Guidance And Margin Outlook Will Support Repricing
Analysts have maintained their $90.00 price target for Establishment Labs Holdings, citing updated assumptions that reflect a lower discount rate, modestly higher revenue growth and profit margin expectations, as well as a slightly reduced future P/E multiple. What's in the News The company issued preliminary revenue guidance for the fourth quarter of 2025, with unaudited revenue expected between $64.0 million and $65.0 million, including $17.0 million to $17.5 million from Motiva sales in the United States (Key Developments).Aggiornamento narrativa • Feb 03
ESTA: Positive EBITDA And U S Expansion Will Support Stronger Forward Outlook
Narrative Update on Establishment Labs Holdings The analyst price target for Establishment Labs Holdings has been lifted from about US$79.67 to roughly US$83.25, as analysts point to recent Q3 revenue and EBITDA beats, an outlook for 2025 revenue above the prior guidance midpoint, and expectations for stronger Motiva sales as key drivers of their updated assumptions. Analyst Commentary Recent research notes give you a clearer picture of how the Street is thinking about Establishment Labs Holdings after its latest Q3 update and guidance commentary.Aggiornamento narrativa • Jan 20
ESTA: First Positive EBITDA And 2025 Outlook Will Support Repricing
Analysts have raised their price target on Establishment Labs Holdings to an implied fair value of $90, up from $70, citing better than expected Q3 results, the first quarter of positive EBITDA, and increased confidence in management's updated revenue expectations for 2025. Analyst Commentary Bullish analysts are framing the recent Q3 report as a key proof point for Establishment Labs Holdings, highlighting that revenue and adjusted EBITDA figures were ahead of prior consensus expectations.Aggiornamento narrativa • Jan 06
ESTA: Q3 Profitability And U.S. Expansion Will Reshape Earnings Profile
Narrative Update The analyst fair value estimate for Establishment Labs Holdings has shifted from US$40.00 to US$75.00. Analysts attributed this change to stronger than expected Q3 revenue, the company’s first quarter of positive EBITDA, increased 2025 revenue expectations, and greater conviction in the U.S. Motiva sales potential as key drivers of their higher price targets.Articolo di analisi • Jan 02
Revenues Not Telling The Story For Establishment Labs Holdings Inc. (NASDAQ:ESTA)
Establishment Labs Holdings Inc.'s ( NASDAQ:ESTA ) price-to-sales (or "P/S") ratio of 11.1x may look like a poor...Aggiornamento narrativa • Dec 20
ESTA: Positive EBITDA And U S Expansion Will Support Measured Forward Outlook
Analysts have modestly increased their price target for Establishment Labs Holdings to approximately $80 per share from about $74, citing stronger than expected Q3 results, the company's first quarter of positive EBITDA, as well as growing confidence in sustained revenue growth and U.S. Motiva sales expansion. Analyst Commentary Street research following the Q3 print reflects a predominantly constructive stance on Establishment Labs, with analysts highlighting both upside drivers and lingering risks that could influence valuation and execution.Aggiornamento narrativa • Dec 05
ESTA: Positive EBITDA And U S Expansion Will Support Balanced Outlook
Analysts have lifted their price target on Establishment Labs Holdings, increasing fair value estimates to about $74 from roughly $71, supported by stronger than expected Q3 results, the company’s first positive EBITDA, and raised 2025 revenue expectations. Analyst Commentary Recent research notes highlight a generally constructive stance on Establishment Labs Holdings, with multiple firms lifting price targets following the latest Q3 results and updated 2025 guidance.Aggiornamento narrativa • Nov 21
ESTA: Continued U S Sales Gains And Improved Margins Will Support Balanced Outlook
Analysts have raised their price target for Establishment Labs Holdings from $62.22 to $71.33 per share, reflecting continued outperformance in Q3 results, improving profit margins, and increased confidence in future revenue growth. Analyst Commentary Analysts have responded to Establishment Labs Holdings' recent performance with revised outlooks, highlighting both areas of strength and potential challenges for the company.Articolo di analisi • Nov 08
US$62.22 - That's What Analysts Think Establishment Labs Holdings Inc. (NASDAQ:ESTA) Is Worth After These Results
A week ago, Establishment Labs Holdings Inc. ( NASDAQ:ESTA ) came out with a strong set of third-quarter numbers that...Aggiornamento narrativa • Nov 07
ESTA: Positive Earnings And U S Market Expansion Will Drive Balanced Outlook
The analyst price target for Establishment Labs Holdings has increased from $55.44 to $62.22 per share. Analysts cite strong Q3 results, improved profit margins, and raised revenue guidance as key drivers of this upward revision.Articolo di analisi • Jul 22
We Think Establishment Labs Holdings (NASDAQ:ESTA) Has A Fair Chunk Of Debt
Legendary fund manager Li Lu (who Charlie Munger backed) once said, 'The biggest investment risk is not the volatility...Nuova narrativa • May 28
Minimally Invasive Procedures Will Expand US And Global Aesthetic Markets
Increasing demand for minimally invasive cosmetic breast procedures and strong U.S. market performance are driving revenue growth and higher margins.Articolo di analisi • Apr 22
The Price Is Right For Establishment Labs Holdings Inc. (NASDAQ:ESTA) Even After Diving 26%
Establishment Labs Holdings Inc. ( NASDAQ:ESTA ) shares have had a horrible month, losing 26% after a relatively good...Articolo di analisi • Apr 09
Here's Why Establishment Labs Holdings (NASDAQ:ESTA) Can Afford Some Debt
The external fund manager backed by Berkshire Hathaway's Charlie Munger, Li Lu, makes no bones about it when he says...Articolo di analisi • Mar 19
What Is Establishment Labs Holdings Inc.'s (NASDAQ:ESTA) Share Price Doing?
Establishment Labs Holdings Inc. ( NASDAQ:ESTA ), might not be a large cap stock, but it received a lot of attention...Articolo di analisi • Mar 01
Establishment Labs Holdings Inc. (NASDAQ:ESTA) Annual Results Just Came Out: Here's What Analysts Are Forecasting For This Year
The investors in Establishment Labs Holdings Inc. 's ( NASDAQ:ESTA ) will be rubbing their hands together with glee...Articolo di analisi • Feb 28
After Leaping 29% Establishment Labs Holdings Inc. (NASDAQ:ESTA) Shares Are Not Flying Under The Radar
Establishment Labs Holdings Inc. ( NASDAQ:ESTA ) shareholders are no doubt pleased to see that the share price has...Articolo di analisi • Jan 14
Establishment Labs Holdings Inc. (NASDAQ:ESTA) Shares Slammed 27% But Getting In Cheap Might Be Difficult Regardless
Establishment Labs Holdings Inc. ( NASDAQ:ESTA ) shares have had a horrible month, losing 27% after a relatively good...Articolo di analisi • Nov 25
Is Establishment Labs Holdings Inc. (NASDAQ:ESTA) Trading At A 21% Discount?
Key Insights The projected fair value for Establishment Labs Holdings is US$54.78 based on 2 Stage Free Cash Flow to...Rendimenti per gli azionisti
| ESTA | US Medical Equipment | US Mercato | |
|---|---|---|---|
| 7D | -8.6% | 0.4% | -1.5% |
| 1Y | 66.5% | -12.6% | 17.9% |
Ritorno vs Industria: ESTA ha superato il US Medical Equipment che ha restituito -12.6 % nell'ultimo anno.
Rendimento vs Mercato: ESTA ha superato il mercato US che ha restituito 17.9 % nell'ultimo anno.
Volatilità dei prezzi
| ESTA volatility | |
|---|---|
| ESTA Average Weekly Movement | 7.0% |
| Medical Equipment Industry Average Movement | 8.4% |
| Market Average Movement | 7.2% |
| 10% most volatile stocks in US Market | 16.3% |
| 10% least volatile stocks in US Market | 3.1% |
Prezzo delle azioni stabile: ESTA non ha avuto una volatilità dei prezzi significativa negli ultimi 3 mesi rispetto al mercato US.
Volatilità nel tempo: La volatilità settimanale ( 7% ) di ESTA è rimasta stabile nell'ultimo anno.
Informazioni sull'azienda
| Fondato | I dipendenti | AMMINISTRATORE DELEGATO | Sito web |
|---|---|---|---|
| 2004 | 1,004 | Fillipo Caldini | www.establishmentlabs.com |
Establishment Labs Holdings Inc. è una società di tecnologia medica che produce e commercializza dispositivi medici per la chirurgia estetica e ricostruttiva del seno in Europa, Medio Oriente, Africa, America Latina, Asia e Stati Uniti. L'azienda offre protesi mammarie in gel di silicone con il marchio Motiva Implants. Fornisce anche espansori del tessuto mammario.
Establishment Labs Holdings Inc. Riepilogo dei fondamenti
| ESTA statistiche fondamentali | |
|---|---|
| Capitalizzazione di mercato | US$2.13b |
| Utili (TTM) | -US$38.89m |
| Ricavi(TTM) | US$245.82m |
8.8x
Rapporto P/S-55.7x
Rapporto P/EESTA è sopravvalutato?
Vedi Fair Value e analisi di valutazioneUtili e ricavi
| ESTA Conto economico (TTM) | |
|---|---|
| Ricavi | US$245.82m |
| Costo del fatturato | US$72.54m |
| Profitto lordo | US$173.27m |
| Altre spese | US$212.17m |
| Utili | -US$38.89m |
Ultimi utili riportati
Jun 30, 2026
Prossima data di guadagno
n/a
| Utile per azione (EPS) | -1.30 |
| Margine lordo | 70.49% |
| Margine di profitto netto | -15.82% |
| Rapporto debito/patrimonio netto | 1,211.2% |
Come si è comportato ESTA nel lungo periodo?
Vedi performance storica e confrontoAnalisi aziendale e situazione dei dati finanziari
| Dati | Ultimo aggiornamento (ora UTC) |
|---|---|
| Analisi dell'azienda | 2026/08/21 07:05 |
| Prezzo dell'azione a fine giornata | 2026/08/21 00:00 |
| Utili | 2026/06/30 |
| Utili annuali | 2025/12/31 |
Fonti dei dati
I dati utilizzati nella nostra analisi aziendale provengono da S&P Global Market Intelligence LLC. I seguenti dati sono utilizzati nel nostro modello di analisi per generare questo report. I dati sono normalizzati, il che può comportare un ritardo nella disponibilità della fonte.
| Pacchetto | Dati | Tempistica | Esempio Fonte USA * |
|---|---|---|---|
| Dati finanziari della società | 10 anni |
| |
| Stime di consenso degli analisti | +3 anni |
|
|
| Prezzi di mercato | 30 anni |
| |
| Proprietà | 10 anni |
| |
| Gestione | 10 anni |
| |
| Sviluppi principali | 10 anni |
|
* Esempio per i titoli statunitensi, per i titoli non statunitensi si utilizzano forme e fonti normative equivalenti.
Se non specificato, tutti i dati finanziari si basano su un periodo annuale ma vengono aggiornati trimestralmente. Si tratta dei cosiddetti dati TTM (Trailing Twelve Month) o LTM (Last Twelve Month). Per saperne di più.
Modello di analisi e Snowflake
I dettagli del modello di analisi utilizzato per generare questo report sono disponibili sulla nostra pagina GitHub; abbiamo anche delle guide su come utilizzare i nostri report e dei tutorial su YouTube.
Scoprite il team di livello mondiale che ha progettato e realizzato il modello di analisi Simply Wall St.
Metriche di settore e industriali
Le nostre metriche di settore e di sezione sono calcolate ogni 6 ore da Simply Wall St; i dettagli del nostro processo sono disponibili su Github.
Fonti analitiche
Establishment Labs Holdings Inc. è coperta da 14 analisti. 9 di questi analisti ha fornito le stime di fatturato o di utile utilizzate come input per il nostro report. Le stime degli analisti vengono aggiornate nel corso della giornata.
| Analista | Istituzione |
|---|---|
| Neil Chatterji | B. Riley Securities, Inc. |
| Sam Eiber | BTIG |
| Michael Gorman | BTIG |